A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies

The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the combination therapy of rituximab, romiplostim, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanyin, Tuncer, Hande
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051095/
https://www.ncbi.nlm.nih.gov/pubmed/30057832
http://dx.doi.org/10.1155/2018/8207017
Descripción
Sumario:The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the combination therapy of rituximab, romiplostim, and mycophenolate and eventually developed thrombocytosis requiring plateletpheresis. Our case highlights the importance of the need to understand predictors of response to standard upfront treatment of acute ITP.

Ejemplares similares